Stem cell-based approaches for macular degeneration are being studied mainly as cell-replacement strategies, particularly through transplantation of retinal pigment epithelial (RPE) cells. Early clinical studies have explored their safety and feasibility, but there is not yet sufficient evidence to consider these approaches an established standard treatment for macular degeneration. 

Key Takeaways

• Stem cell-based approaches for macular degeneration are being studied mainly through transplantation of retinal pigment epithelial (RPE) cells, particularly in research involving atrophic or non-neovascular disease.
• Researchers are investigating different cell sources, including adult RPE-derived cells and pluripotent stem cell-derived RPE cells.
• Early clinical studies have reported encouraging safety findings, but the evidence is still developing and does not establish stem cell therapy as a routine treatment for macular degeneration.
• Clinical trials are evaluating whether transplanted RPE cells can survive, integrate with retinal tissue, and potentially preserve or improve vision.
• Results from small or early-stage studies should not be interpreted as a guaranteed outcome for individual patients.
• Patients considering these approaches should discuss the type of macular degeneration, treatment evidence, potential risks, and clinical-trial status with a qualified eye specialist.

Stem Cell Therapy for Macular Degeneration Explained

For a patient living with macular degeneration, the gradual vision changes may become noticeable in everyday moments. This makes it hard to read a message, recognise faces, or look at fine details that may gradually become an everyday struggle. It becomes natural for patients to wonder whether damaged retinal cells can be replaced or lost vision can be restored. 

This is one reason researchers are investigating cell-based approaches for macular degeneration. Rather than assuming that transplanted cells can restore vision, current studies are examining whether specific retinal cells, particularly RPE cells, can be safely transplanted and function within the damaged retina. However, the research is still developing, and understanding what has actually been found in clinical studies is important before considering any stem cell-based or regenerative approaches. 

What Is Macular Degeneration?

Macular degeneration is an eye condition that affects a person’s macula, the central part of the retina responsible for detailed vision. A person may first notice it during daily activities, such as reading small print, recognising faces, or seeing straight lines clearly. Peripheral vision is usually less affected. 

The two types of macular degeneration include:

• Dry AMD: The more common form of AMD, involving gradual changes and loss of retinal cells and supporting tissues in the macula. Advanced dry AMD can include geographic atrophy, in which areas of retinal tissue are progressively lost.

• Neovascular (Wet) AMD: A form of AMD in which abnormal blood vessels grow beneath or into the retina and can leak fluid or blood, potentially causing more rapid changes in central vision.

How Are Stem Cell-Derived RPE Cells Being Studied for Macular Degeneration?

Researchers are investigating whether retinal pigment epithelial cells generated from stem cells may be transplanted into areas affected by retinal degeneration. The objective is to determine whether these cells can survive, remain functional, and interact appropriately with the surrounding retinal area. 

The research is mainly examining whether cell-based approaches could:

• Replace cells that have been lost or damaged
• Support the remaining retinal tissue
• Help preserve visual function
• Remain viable and functional over time

These questions are being evaluated through preclinical research and early-stage clinical studies. The important issue is not simply whether cells can be delivered into the eye, but whether they can remain safe and function appropriately over time.

What Types of Stem Cell Therapies Are Being Studied for Macular Degeneration?

There is currently no single standard stem cell-based approach for macular degeneration. Research is exploring different sources of retinal cells and different ways of delivering them to the eye.

Some of the approaches being investigated include:

• iPSC-Derived RPE Cells: Researchers can reprogram adult cells into induced pluripotent stem cells and differentiate them into RPE cells for study and transplantation.

• RPE-Derived or Progenitor Cell Approaches: Other studies have investigated retinal cells or progenitor populations with potential applications in cell replacement.

• Different Delivery Formats: Research has explored RPE cells delivered as suspensions, sheets, strips, or other preparations.

For patients, this distinction matters because cell source, delivery method, and clinical evidence may differ considerably between approaches. A treatment simply named as stem cell therapy may therefore represent very different research methods and levels of evidence. 

What Does Clinical Research Show So Far? 

Some early clinical research suggests that some stem cell-based approaches are feasible and have shown some encouraging safety findings, but researchers are still investigating to understand whether they can produce meaningful and lasting changes in vision. 

Some important findings so far include:

• Safety and Feasibility: Early clinical studies have primarily assessed whether specific cell products and transplantation procedures can be delivered safely and whether transplanted cells can survive or remain detectable after transplantation.

• Visual Outcomes: Some early studies have reported changes in visual or retinal measurements, but small sample sizes, different study designs, and other methodological limitations make it difficult to determine whether these findings demonstrate consistent treatment effectiveness.

• Small sample sizes: A lot of the research involves a small number of subjects, so the results cannot be universally generalised.

• Different outcomes: Trials use different cell products, doses, delivery methods, and measures of vision, making direct comparisons difficult.

Because studies use different cell products, patient populations, delivery methods, and outcome measures, there is currently no reliable single success rate that can be applied to stem cell-based treatment for macular degeneration.

What Are the Potential Risks and Limitations of Stem Cell Therapy?

For patients seeking these emerging approaches for eye treatment, understanding the delays as well as the potential benefits is important. Stem cell-based approaches are still being investigated, so risks may arise from both the procedure itself and the behaviour of transplanted cells. 

Some concerns include:

• Procedure-related Risks: Delivering cells to the retina may involve a subretinal process, which carries risks associated with eye surgery.

• Immune Response: The patient’s body may react to transplanted cells, based on the cell source and treatment approach.

• Uncontrolled Cell Growth: Stem cell-derived products require careful characterisation and monitoring because unwanted cell growth or abnormal tissue formation is an important safety consideration in cell-based research.

• Long-term Uncertainty: It is still being studied how long transplanted cells survive, how well they function, and whether any visual effects can be maintained.

• Limited Evidence: Small clinical studies cannot yet tell us how an individual patient will respond.

• Surgical Risks: Some retinal cell-transplantation approaches involve surgical delivery, such as subretinal transplantation. The procedure itself may carry risks that are separate from the biological effects of the transplanted cells.

For this reason, patients should look beyond the phrase “stem cell therapy” and ask about the specific cell product, procedure, clinical evidence, potential risks, and current regulatory or trial status.

Looking Ahead

Stem cell-based approaches for macular degeneration remain an active area of retinal research, particularly the transplantation of RPE cells derived from different cell sources. Early clinical studies have provided important information about feasibility and safety, but questions about long-term cell survival, functional integration, and meaningful visual benefit remain.

For patients with macular degeneration, the specific type and stage of disease, existing treatment options, and evidence supporting any proposed cell-based approach should be discussed with a qualified ophthalmologist before considering an investigational treatment.

Frequently Asked Questions

Q1. Can damaged vision from macular degeneration come back?

Not necessarily. The outcome depends on the type and stage of macular degeneration and the extent of retinal damage. Stem cell research is investigating whether damaged retinal cells can be supported or replaced, but restoration of vision is not established.

Q2. Is stem cell therapy FDA-approved for macular degeneration?

The FDA has not approved stem cell products for treating macular degeneration. Patients should verify the regulatory status of any proposed cell-based intervention and distinguish approved care from investigational clinical research. 

Q3. How do doctors determine whether a patient is suitable?

Doctors may consider the type and stage of AMD, visual acuity, retinal imaging, eye health, medical history, and previous treatments. Eligibility can also depend on the specific clinical protocol being considered. 

Q4. Should I stop my current AMD treatment before considering stem cells?

No. Patients should not stop prescribed eye treatment on their own. Any change to an existing treatment plan should be discussed with the ophthalmologist managing their condition.

Q5. Can international patients explore stem cell research for macular degeneration in India?

International patients can seek medical guidance before making travel arrangements. Sharing relevant medical records with a qualified medical team can help determine what further evaluation or discussion may be appropriate.

Q6. What should I ask before agreeing to a stem cell procedure?

The patient needs to know about what kind of cells would be used, whether it forms part of an approved clinical trial, what evidence backs up the therapy, what the risks are, and how the outcome would be measured.

Q7. Can stem cell therapy replace regular eye care?

No. Some emerging cell-based approaches should not be considered as an alternative to standard care. Patients with macular degeneration are advised to continue regular monitoring and discuss all treatment options with their eye specialist. 

Reference Links

(1) Babighian, S., Zanella, M. S., Gattazzo, I., Galan, A., Gagliano, C., D’Esposito, F., & Zeppieri, M. (2025). Atrophic Macular Degeneration and Stem Cell Therapy: A Clinical Review. Advances in Experimental Medicine and Biology. DOI: 10.1007/5584_2024_819.

https://pubmed.ncbi.nlm.nih.gov/39259423/

(2) Hwang, et al. (2025). hPSC-based treatment of retinal diseases: Current progress and challenges. Advanced Drug Delivery Reviews. DOI: 10.1016/j.addr.2025.115587.

https://pubmed.ncbi.nlm.nih.gov/40228605/

(3) Bracha, P., Moore, N. A., & Ciulla, T. A. (2017). Induced pluripotent stem cell-based therapy for age-related macular degeneration. Expert Opinion on Biological Therapy, 17(9), 1113–1126. DOI: 10.1080/14712598.2017.1346079.

https://pubmed.ncbi.nlm.nih.gov/28664762/

(4) National Eye Institute. Age-Related Macular Degeneration (AMD). National Institutes of Health.

https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration

(5) National Eye Institute. Clinical Trial Highlight: Stem Cell Transplants for Dry AMD. National Institutes of Health.

https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration/clinical-trial-highlight-stem-cell-transplants-dry-amd

Medical Disclaimer

This blog is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Stem cell-based approaches for macular degeneration are still being studied, and their clinical evidence and regulatory status may vary by intervention and location. Patients should consult a qualified ophthalmologist or other appropriate healthcare professional before making decisions about treatment or participation in clinical research.